PRESS RELEASE
News
-
-
PRESS RELEASE
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Sonnet BioTherapeutics announces financial results and corporate updates including Phase 1 data on SON-1010 safety, net proceeds from tax program, and clinical trial progress on SON-080 for CIPN -
PRESS RELEASE
NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du poumon de stade trois
Nanobiotix annonce l'acceptation par la FDA d'un protocole pour une nouvelle étude de phase 2 sur NBTXR3 pour le cancer du poumon de stade III -
-
-
-
PRESS RELEASE
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Protagonist Therapeutics to present rusfertide Phase 2 REVIVE study data at EHA Congress in Madrid. Study shows absence of QTc prolongation with rusfertide. Details on pipeline drugs and collaborations available on company's website -
-
PRESS RELEASE
Hamilton Health Box Raises $10 Million in Series A Funding to Accelerate Rural Market Expansion
Hamilton Health Box secures $10M Series A funding to expand into rural America, addressing Health Professional Shortage Areas. The unique microclinic model offers affordable primary care services -
